3 Healthcare Stocks Topping a 2025 List of Dividend Yields

The article highlights Bristol Myers Squibb, Pfizer, and Dentsply Sirona as high-yield healthcare stocks that, despite recent underperformance and low valuations, present potential investment opportunities rather than 'yield traps.' Bristol Myers Squibb (5.3% yield) is demonstrating growth from new drugs countering generic competition, while Pfizer (7% yield) is strategically addressing its patent cliff and entering the anti-obesity market via a $10 billion acquisition of Metsera. Dentsply Sirona (5.7% yield), facing sales declines and management changes, offers a substantial dividend as a new CEO implements a turnaround strategy, suggesting these stocks could offer both income and future appreciation.

Analysis

The article identifies Bristol Myers Squibb (BMY), Pfizer (PFE), and Dentsply Sirona (XRAY) as high-yield healthcare stocks that, despite low valuations and recent underperformance, offer potential investment opportunities beyond typical 'yield traps.' BMY trades at 7.5x forward earnings with a 5.3% yield, PFE at 9x with a 7% yield, and XRAY at 6.5x with a 5.7% yield, indicating market skepticism regarding their growth prospects.

Bristol Myers Squibb is demonstrating a potential exit from a growth slump, with Q3 sales increasing 3% and adjusted EPS of $1.63 beating estimates by $0.12, driven by its 'growth portfolio' countering generic competition. Pfizer is strategically addressing its patent cliff by acquiring Metsera for $10 billion, positioning itself in the high-growth anti-obesity market, which could drive significant earnings and valuation expansion compared to peers like Novo Nordisk (14x P/E) and Eli Lilly (27x P/E).

Dentsply Sirona faces headwinds including declining sales and C-suite changes, but its new CEO is implementing a 'return-to-growth action plan.' While awaiting a potential turnaround, the company's 5.7% dividend yield offers investors income, providing a 'get paid while you wait' scenario. All three companies maintain consistent dividend histories, offering a buffer during periods of transition or growth acceleration.

These companies represent situations where current low valuations may not fully reflect their respective catalysts, such as BMY's new drug pipeline, PFE's strategic M&A, or XRAY's turnaround efforts, alongside attractive dividend income.

Key Decisions for Investors

• Monitor Bristol Myers Squibb's 'growth portfolio' performance and subsequent earnings guidance for sustained recovery and potential re-rating.
• Evaluate Pfizer's strategic integration of Metsera and the development of its anti-obesity drug pipeline as a key driver for significant future growth and valuation expansion.
• Track Dentsply Sirona's new CEO's 'return-to-growth action plan' execution and management stability as critical indicators for a successful turnaround.
• Assess the role of these companies' high dividend yields in providing income and potential downside protection while awaiting the realization of their respective growth catalysts.